LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 104

Search options

  1. Article ; Online: Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy.

    Hertz, Daniel L

    Current opinion in supportive and palliative care

    2024  Volume 18, Issue 1, Page(s) 30–38

    Abstract: Purpose of review: This review aims to provide insights into persistent taxane-induced peripheral neuropathy (TIPN). The primary objective is to describe the incidence, predictors, and consequences of TIPN lasting at least 1 year after the end of taxane ...

    Abstract Purpose of review: This review aims to provide insights into persistent taxane-induced peripheral neuropathy (TIPN). The primary objective is to describe the incidence, predictors, and consequences of TIPN lasting at least 1 year after the end of taxane treatment.
    Recent findings: Studies show varying rates of TIPN persistence, with an estimated 30-40% and 40-60% resolving by 1- and 3-year post-treatment. TIPN in the feet and motor symptoms show less resolution post-treatment. Patients who are older or have higher body weight may experience less TIPN resolution, but results may be confounded by TIPN development during treatment. Persistent TIPN negatively impacts long-term functional ability, including gait, balance, and the ability to work. It also reduces overall quality of life (QOL), particularly affecting physical and social aspects.
    Summary: Clinicians should be aware of the potential for persistent TIPN and its impact on patients' function and QOL. Future research should focus on large prospective studies with systematic TIPN assessments during and after treatment to better understand which symptoms and patient characteristics predict resolution. This information can guide treatment decisions, balancing the need for effective chemotherapy with minimizing long-term impairments in function and QOL.
    MeSH term(s) Humans ; Quality of Life ; Prospective Studies ; Incidence ; Taxoids/adverse effects ; Peripheral Nervous System Diseases/chemically induced ; Peripheral Nervous System Diseases/epidemiology ; Bridged-Ring Compounds
    Chemical Substances taxane (1605-68-1) ; Taxoids ; Bridged-Ring Compounds
    Language English
    Publishing date 2024-12-06
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 2633726-5
    ISSN 1751-4266 ; 1751-4258
    ISSN (online) 1751-4266
    ISSN 1751-4258
    DOI 10.1097/SPC.0000000000000684
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Reply to H.S. Hochster.

    Hertz, Daniel L

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2023  Volume 41, Issue 11, Page(s) 2120–2121

    Language English
    Publishing date 2023-02-10
    Publishing country United States
    Document type Research Support, Non-U.S. Gov't ; Letter ; Comment
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.23.00038
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Assessment of the Clinical Utility of Pretreatment

    Hertz, Daniel L

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2022  Volume 40, Issue 33, Page(s) 3882–3892

    Abstract: Purpose: Patients who carry pathogenic variants in : Methods: This special article uses previously published frameworks for assessing the clinical utility of cancer biomarker tests, including for germline indicators of toxicity risk, to assess the ... ...

    Abstract Purpose: Patients who carry pathogenic variants in
    Methods: This special article uses previously published frameworks for assessing the clinical utility of cancer biomarker tests, including for germline indicators of toxicity risk, to assess the clinical utility of pretreatment
    Results: There is no direct evidence of efficacy reduction, and the available indirect evidence demonstrates that
    Conclusion: This article should serve as a call to action for clinicians and clinical guidelines committees in the United States to re-evaluate the clinical utility of pretreatment
    MeSH term(s) Humans ; Dihydrouracil Dehydrogenase (NADP)/genetics ; Heterozygote ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Risk ; Europe ; Fluorouracil/adverse effects
    Chemical Substances Dihydrouracil Dehydrogenase (NADP) (EC 1.3.1.2) ; Fluorouracil (U3P01618RT)
    Language English
    Publishing date 2022-09-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.22.00037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.

    Hertz, Daniel L

    Expert opinion on drug metabolism & toxicology

    2021  Volume 17, Issue 2, Page(s) 227–239

    Abstract: ... ...

    Abstract Introduction
    MeSH term(s) Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Biomarkers/analysis ; Docetaxel/administration & dosage ; Docetaxel/adverse effects ; Docetaxel/pharmacokinetics ; Dose-Response Relationship, Drug ; Humans ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Paclitaxel/pharmacokinetics ; Peripheral Nervous System Diseases/chemically induced ; Peripheral Nervous System Diseases/genetics ; Pharmacogenetics ; Precision Medicine
    Chemical Substances Antineoplastic Agents ; Biomarkers ; Docetaxel (15H5577CQD) ; Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2021-01-06
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2214462-6
    ISSN 1744-7607 ; 1742-5255
    ISSN (online) 1744-7607
    ISSN 1742-5255
    DOI 10.1080/17425255.2021.1856367
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Using maximum plasma concentration (C

    Sun, Yuchen / Cheng, Yue / Hertz, Daniel L

    Cancer chemotherapy and pharmacology

    2024  

    Abstract: Taxanes are a widely used class of anticancer agents that play a vital role in the treatment of a variety of cancers. However, toxicity remains a major concern of using taxane drugs as some toxicities are highly prevalent, they can not only adversely ... ...

    Abstract Taxanes are a widely used class of anticancer agents that play a vital role in the treatment of a variety of cancers. However, toxicity remains a major concern of using taxane drugs as some toxicities are highly prevalent, they can not only adversely affect patient prognosis but also compromise the overall treatment plan. Among all kinds of factors that associated with taxane toxicity, taxane exposure has been extensively studied, with different pharmacokinetic (PK) parameters being used as toxicity predictors. Compared to other widely used predictors such as the area under the drug plasma concentration curve versus time (AUC) and time above threshold plasma drug concentration, maximum plasma concentration (C
    Language English
    Publishing date 2024-05-11
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 6820-2
    ISSN 1432-0843 ; 0344-5704 ; 0943-9404
    ISSN (online) 1432-0843
    ISSN 0344-5704 ; 0943-9404
    DOI 10.1007/s00280-024-04677-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Chemotherapy-Induced Peripheral Neuropathy.

    Chen, Ciao-Sin / Hertz, Daniel L

    Handbook of experimental pharmacology

    2022  Volume 277, Page(s) 299–337

    Abstract: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of many common anti-cancer agents that can lead to dose reduction or treatment discontinuation, which decrease chemotherapy efficacy. Long-term CIPN can interfere with ... ...

    Abstract Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of many common anti-cancer agents that can lead to dose reduction or treatment discontinuation, which decrease chemotherapy efficacy. Long-term CIPN can interfere with activities of daily living and diminish the quality of life. The mechanism of CIPN is not yet fully understood, and biomarkers are needed to identify patients at high risk and potential treatment targets. Metabolomics can capture the complex behavioral and pathophysiological processes involved in CIPN. This chapter is to review the CIPN metabolomics studies to find metabolic pathways potentially involved in CIPN. These potential CIPN metabolites are then investigated to determine whether there is evidence from studies of other neuropathy etiologies such as diabetic neuropathy and Leber hereditary optic neuropathy to support the importance of these pathways in peripheral neuropathy. Six potential biomarkers and their putative mechanisms in peripheral neuropathy were reviewed. Among these biomarkers, histidine and phenylalanine have clear roles in neurotransmission or neuroinflammation in peripheral neuropathy. Further research is needed to discover and validate CIPN metabolomics biomarkers in large clinical studies.
    MeSH term(s) Humans ; Quality of Life ; Activities of Daily Living ; Peripheral Nervous System Diseases/chemically induced ; Peripheral Nervous System Diseases/therapy ; Antineoplastic Agents
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2022-10-17
    Publishing country Germany
    Document type Journal Article
    ISSN 0171-2004
    ISSN 0171-2004
    DOI 10.1007/164_2022_609
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy.

    Hertz, Daniel L

    The pharmacogenomics journal

    2019  Volume 19, Issue 5, Page(s) 411–416

    MeSH term(s) Antineoplastic Agents/adverse effects ; Biomarkers ; Humans ; Patient Reported Outcome Measures ; Peripheral Nervous System Diseases/chemically induced ; Pharmacogenetics
    Chemical Substances Antineoplastic Agents ; Biomarkers
    Language English
    Publishing date 2019-08-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2106831-8
    ISSN 1473-1150 ; 1470-269X
    ISSN (online) 1473-1150
    ISSN 1470-269X
    DOI 10.1038/s41397-019-0093-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Evolution of predictive risk factor analysis for chemotherapy-related toxicity.

    Hertz, Daniel L / Lustberg, Maryam B / Sonis, Stephen

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

    2023  Volume 31, Issue 10, Page(s) 601

    Abstract: The causes of variation in toxicity to the same treatment regimen among seemingly similar patients remain largely unknown. There was tremendous optimism that the patient's germline genome would be strongly predictive of treatment-related toxicity and ... ...

    Abstract The causes of variation in toxicity to the same treatment regimen among seemingly similar patients remain largely unknown. There was tremendous optimism that the patient's germline genome would be strongly predictive of treatment-related toxicity and could be used to personalize treatment and improve therapeutic outcomes. However, there has been limited success in discovering robust pharmacogenetic predictors of treatment-related toxicity and even less progress in translating the few validated predictors into clinical practice. It is apparent that identification of toxicity predictors that can be used to predict and prevent treatment-related toxicity will require thinking beyond germline genomics. To that end, we propose an integrated biomarker discovery approach that recognizes that a patient's toxicity risk is determined by the cumulative effects of a broad range of "omic" and non-omic factors. This commentary describes the limited success in discovering and translating clinical and pharmacogenetic toxicity predictors into clinical practice. We illustrate the evolution of cancer toxicity biomarker discovery and translation through studies of taxane-induced peripheral neuropathy, which is one of the most common and debilitating side effects of cancer treatment. We then discuss the opportunities for discovering non-genomic (e.g., metabolomic, lipidomic, transcriptomic, proteomic, microbiomic, medical, behavioral, environmental) and integrated biomarkers that may be more strongly predictive of toxicity risk and the potential challenges with translating integrated biomarkers into clinical practice. This integrated biomarker discovery approach may circumvent some of the major limitations in toxicity biomarker science and move precision oncology treatment forward so that patients receive maximum treatment benefit with minimal toxicity.
    MeSH term(s) Humans ; Proteomics ; Neoplasms/drug therapy ; Neoplasms/genetics ; Precision Medicine ; Biomarkers, Tumor ; Risk Factors
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2023-09-29
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 1134446-5
    ISSN 1433-7339 ; 0941-4355
    ISSN (online) 1433-7339
    ISSN 0941-4355
    DOI 10.1007/s00520-023-08074-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Including DPYD on Cancer Genetic Panels to Prevent Fatal Fluoropyrimidine Toxicity.

    Hertz, Daniel L / Sahai, Vaibhav

    Journal of the National Comprehensive Cancer Network : JNCCN

    2020  Volume 18, Issue 4, Page(s) 372–374

    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers ; Drug-Related Side Effects and Adverse Reactions/etiology ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Genetic Testing ; Humans ; Mutation ; Neoplasms/complications ; Neoplasms/drug therapy ; Neoplasms/genetics ; Pharmacogenomic Variants ; Polymorphism, Single Nucleotide ; Prognosis ; Pyrimidines/adverse effects ; Pyrimidines/therapeutic use ; Treatment Outcome
    Chemical Substances Biomarkers ; Pyrimidines ; pyrimidine (K8CXK5Q32L)
    Language English
    Publishing date 2020-04-05
    Publishing country United States
    Document type Letter
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2019.7527
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective.

    Hertz, Daniel L / McShane, Lisa M / Hayes, Daniel F

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2022  Volume 40, Issue 16, Page(s) 1721–1731

    MeSH term(s) Germ Cells ; Germ-Line Mutation ; Humans
    Language English
    Publishing date 2022-03-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.21.02209
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top